You're right. 140% increase in product sales revenues in Q216 vs a year earlier isn't very good. The 60%+ gross margin stinks also. Probably not very important also that the largest dialysis company in the world started marketing and selling the product last quarter either. Or that one of the big 3 global companies in cardiac surgery just started selling CytoSorb this quarter. I see your point. There must be something else out there with better numbers, that include: CytoSorb® product sales for Q2 2016 were a record $1.9 million. This represents an increase of approximately 140% over Q2 2015 product sales of $0.8 million, as a result of strong increases in both direct and distributor sales
Second quarter 2016 annualized product sales run rate was approximately $7.4 million, as compared to an annualized product sales run rate of approximately $3.1 million in the second quarter of 2015
Total revenue for the second quarter of 2016 was $2.2 million, which includes both product sales and grant revenue
Overall gross margins rose to approximately $1.3 million in Q2 2016, representing an increase of approximately $0.8 million as compared to approximately $0.5 million in Q2 2015
Product gross margins for Q2 2016 increased to 68% compared to approximately 63% for Q2 2015. Maybe I should check back in 2017 when annual sales more than double again, and perhaps again.
News 
Market Data 
Discover 
